FDA Warning Letter Explorer
Drugs · Letter issue date: Sep 9, 2025

Healthon Inc. dba Healthon

4 extracted findings · 1 model-assigned issue type

FDA source excerpt, selected passage

“Same active ingredient as Wegovy and Ozempic.”

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Labeling, claims & marketing

Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.

Supporting FDA text
Source excerpt · automated text-match check

“Same active ingredient as Wegovy and Ozempic.”

Labeling, claims & marketing

Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.

Supporting FDA text
Source excerpt · automated text-match check

“Same active ingredient as Mounjaro pens and Zepbound.”

Labeling, claims & marketing

Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.

Supporting FDA text
Source excerpt · automated text-match check

“Clinically proven weight loss”

Labeling, claims & marketing

Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.

Supporting FDA text
Source excerpt · automated text-match check

“The active ingredient in our formula is FDA-approved….”

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
“Same active ingredient as Wegovy and Ozempic.”

Source passage selected by the model

02
“Same active ingredient as Mounjaro pens and Zepbound.”

Source passage selected by the model

03
“Clinically proven weight loss”

Source passage selected by the model

04
“The active ingredient in our formula is FDA-approved….”

Source passage selected by the model

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • Provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps taken to address any violations
  • Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation
  • If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration
  • If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.